170 related articles for article (PubMed ID: 22072540)
21. BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients.
Damiani D; Tiribelli M; Franzoni A; Michelutti A; Fabbro D; Cavallin M; Toffoletti E; Simeone E; Fanin R; Damante G
Am J Hematol; 2013 Oct; 88(10):848-52. PubMed ID: 23760853
[TBL] [Abstract][Full Text] [Related]
22. Relation of BAALC and ERG Gene Expression with Overall Survival in Acute Myeloid Leukemia Cases.
Rashed RA; Kadry DY; El Taweel M; Abd El Wahab N; Abd El Hameed T
Asian Pac J Cancer Prev; 2015; 16(17):7875-82. PubMed ID: 26625814
[TBL] [Abstract][Full Text] [Related]
23. Meningioma 1 (MN1) expression: refined risk stratification in acute myeloid leukemia with normal cytogenetics (CN-AML).
Aref S; Ibrahim L; Morkes H; Azmy E; Ebrahim M
Hematology; 2013 Sep; 18(5):277-83. PubMed ID: 23394438
[TBL] [Abstract][Full Text] [Related]
24. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
[TBL] [Abstract][Full Text] [Related]
25. Implication of higher BAALC expression in combination with other gene mutations in adult cytogenetically normal acute myeloid leukemia.
Yoon JH; Kim HJ; Shin SH; Yahng SA; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Lim JH
Leuk Lymphoma; 2014 Jan; 55(1):110-20. PubMed ID: 23647058
[TBL] [Abstract][Full Text] [Related]
26. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.
Thol F; Damm F; Lüdeking A; Winschel C; Wagner K; Morgan M; Yun H; Göhring G; Schlegelberger B; Hoelzer D; Lübbert M; Kanz L; Fiedler W; Kirchner H; Heil G; Krauter J; Ganser A; Heuser M
J Clin Oncol; 2011 Jul; 29(21):2889-96. PubMed ID: 21670448
[TBL] [Abstract][Full Text] [Related]
27. Integrative prognostic risk score in acute myeloid leukemia with normal karyotype.
Damm F; Heuser M; Morgan M; Wagner K; Görlich K; Grosshennig A; Hamwi I; Thol F; Surdziel E; Fiedler W; Lübbert M; Kanz L; Reuter C; Heil G; Delwel R; Löwenberg B; Valk PJ; Krauter J; Ganser A
Blood; 2011 Apr; 117(17):4561-8. PubMed ID: 21372155
[TBL] [Abstract][Full Text] [Related]
28. Development of gene expression-based risk score in cytogenetically normal acute myeloid leukemia patients.
Bou Samra E; Klein B; Commes T; Moreaux J
Oncotarget; 2012 Aug; 3(8):824-32. PubMed ID: 22910040
[TBL] [Abstract][Full Text] [Related]
29. The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia.
Díaz-Beyá M; Brunet S; Nomdedéu J; Cordeiro A; Tormo M; Escoda L; Ribera JM; Arnan M; Heras I; Gallardo D; Bargay J; Queipo de Llano MP; Salamero O; Martí JM; Sampol A; Pedro C; Hoyos M; Pratcorona M; Castellano JJ; Nomdedeu M; Risueño RM; Sierra J; Monzó M; Navarro A; Esteve J
Blood Cancer J; 2015 Oct; 5(10):e352. PubMed ID: 26430723
[TBL] [Abstract][Full Text] [Related]
30. Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia.
Santamaría CM; Chillón MC; García-Sanz R; Pérez C; Caballero MD; Ramos F; de Coca AG; Alonso JM; Giraldo P; Bernal T; Queizán JA; Rodriguez JN; Fernández-Abellán P; Bárez A; Peñarrubia MJ; Balanzategui A; Vidriales MB; Sarasquete ME; Alcoceba M; Díaz-Mediavilla J; San Miguel JF; Gonzalez M
Blood; 2009 Jul; 114(1):148-52. PubMed ID: 19398719
[TBL] [Abstract][Full Text] [Related]
31. High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study.
Langer C; Radmacher MD; Ruppert AS; Whitman SP; Paschka P; Mrózek K; Baldus CD; Vukosavljevic T; Liu CG; Ross ME; Powell BL; de la Chapelle A; Kolitz JE; Larson RA; Marcucci G; Bloomfield CD;
Blood; 2008 Jun; 111(11):5371-9. PubMed ID: 18378853
[TBL] [Abstract][Full Text] [Related]
32. The Prognostic Relevance of BAALC and ERG Expression Levels in Cytogenetically Normal Pediatric Acute Myeloid Leukemia.
Aref S; Al Khodary T; Zeed TA; El Sadiek A; El Menshawy N; Al Ashery R
Indian J Hematol Blood Transfus; 2015 Mar; 31(1):21-8. PubMed ID: 25548440
[TBL] [Abstract][Full Text] [Related]
33. The clinical relevance of BAALC and ERG expression levels in pediatric AML.
Hermkens MC; van den Heuvel-Eibrink MM; Arentsen-Peters ST; Baruchel A; Stary J; Reinhardt D; Zimmerman M; de Haas V; Pieters R; Zwaan CM
Leukemia; 2013 Mar; 27(3):735-7. PubMed ID: 22895118
[No Abstract] [Full Text] [Related]
34. BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study.
Baldus CD; Tanner SM; Ruppert AS; Whitman SP; Archer KJ; Marcucci G; Caligiuri MA; Carroll AJ; Vardiman JW; Powell BL; Allen SL; Moore JO; Larson RA; Kolitz JE; de la Chapelle A; Bloomfield CD
Blood; 2003 Sep; 102(5):1613-8. PubMed ID: 12750167
[TBL] [Abstract][Full Text] [Related]
35. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
[TBL] [Abstract][Full Text] [Related]
36. High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics.
Heuser M; Beutel G; Krauter J; Döhner K; von Neuhoff N; Schlegelberger B; Ganser A
Blood; 2006 Dec; 108(12):3898-905. PubMed ID: 16912223
[TBL] [Abstract][Full Text] [Related]
37. BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML).
Santamaría C; Chillón MC; García-Sanz R; Pérez C; Caballero MD; Mateos MV; Ramos F; de Coca AG; Alonso JM; Giraldo P; Bernal T; Queizán JA; Rodríguez JN; Puig N; Balanzategui A; Sarasquete ME; Alcoceba M; Díaz-Mediavilla J; San Miguel J; González M
Ann Hematol; 2010 May; 89(5):453-8. PubMed ID: 19943049
[TBL] [Abstract][Full Text] [Related]
38. GAS6 expression identifies high-risk adult AML patients: potential implications for therapy.
Whitman SP; Kohlschmidt J; Maharry K; Volinia S; Mrózek K; Nicolet D; Schwind S; Becker H; Metzeler KH; Mendler JH; Eisfeld AK; Carroll AJ; Powell BL; Carter TH; Baer MR; Kolitz JE; Park IK; Stone RM; Caligiuri MA; Marcucci G; Bloomfield CD
Leukemia; 2014 Jun; 28(6):1252-1258. PubMed ID: 24326683
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of immunophenotyping and gene mutations in elderly patients with acute myeloid leukemia with normal karyotype.
Dang H; Jiang A; Kamel-Reid S; Brandwein J; Chang H
Hum Pathol; 2013 Jan; 44(1):55-61. PubMed ID: 22939316
[TBL] [Abstract][Full Text] [Related]
40. Prognostic implication of BAALC gene expression in adult acute myeloid leukemia.
Yahya RS; Sofan MA; Abdelmasseih HM; Saudy N; Sharaf-Eldein MA
Clin Lab; 2013; 59(5-6):621-8. PubMed ID: 23865362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
